Berobenatide: Pfizer's Monthly GLP-1, VESPER-3 Phase 2b Evidence

The headline

On June 6, 2026, at the ADA 86th Scientific Sessions in Chicago, Pfizer reported Phase 2b results from VESPER-3, the first dedicated test of whether berobenatide (PF-07976016) can deliver useful weight loss on a once-monthly subcutaneous dose. At the 4.8 mg monthly dose, the trial reported up to 12.3% placebo-adjusted body weight loss at 28 weeks. A parallel 32-week open-label extension of the earlier VESPER-1 weekly trial showed non-placebo-adjusted weight loss of 15.9% to 16.8% on weekly 1.6 to 2.4 mg doses, with no plateau yet.

That is the first GLP-1 weight loss readout where the maintenance dose interval is monthly rather than weekly, and it is the dataset that will drive Pfizer's Phase 3 design. Three points matter for how to read it:

1. The trial used a hybrid schedule. Participants received weekly dosing during titration through week 12, then transitioned to monthly dosing through week 28. The monthly headline is real, but only for the maintenance phase.
2. Press release and ADA late-breaker only. As of June 2026, VESPER-3 has not been peer-reviewed. Numbers are from the Pfizer release dated June 5, 2026, and the ADA presentation. Detailed efficacy curves, safety subgroup analyses, and dose-response shape are pending the manuscript.
3. The comparator floor was placebo. Berobenatide has not run head-to-head against semaglutide, tirzepatide, or maridebart cafraglutide (MariTide), the only other monthly GLP-1-class candidate with human data.

Bottom line: Berobenatide cleared the proof-of-concept bar for monthly GLP-1 maintenance dosing. The Phase 2b efficacy is meaningful but trails the weekly best-in-class numbers. The competitive question is no longer "can monthly work?" but "is monthly worth losing efficacy?"

What VESPER-3 measured

VESPER-3 was a Phase 2b trial in adults with overweight or obesity, with and without type 2 diabetes. It tested whether a participant titrated to a weekly maintenance dose could be transitioned to a monthly maintenance dose without losing weight or tolerability. Four monthly maintenance dose regimens were studied, with two titration steps and weekly dosing carried through week 12 before the monthly maintenance phase began.

Headline efficacy

• Placebo-adjusted weight loss at 28 weeks: up to 12.3% at 4.8 mg monthly in participants without T2D
• Primary endpoint of body weight change versus placebo was superior in all four monthly dose regimens
• The release did not publish dose-by-dose efficacy curves

Companion VESPER-1 32-week extension

The same Pfizer release reported a 32-week open-label extension of the earlier VESPER-1 weekly-dose Phase 2b. Participants who escalated from placebo to 1.6 mg or 2.4 mg weekly berobenatide reached non-placebo-adjusted weight loss of 15.9% to 16.8% at 32 weeks. The curve had not plateaued.

The VESPER-1 number is the bigger one in coverage, but it is from a weekly-dose extension, not a monthly-dose head-to-head. The two trials answer different questions. VESPER-3 is the one that justifies the Phase 3 monthly schedule.

Why monthly dosing is engineering, not biology

The native GLP-1 hormone has a circulating half-life of about two minutes. Every clinically useful GLP-1 receptor agonist is a deliberate engineering exercise: a modification that protects the peptide from dipeptidyl peptidase-4 (DPP-4) degradation, plus a strategy that drags the plasma half-life out from minutes to days or weeks.

For weekly compounds, the engineering trick is fatty acid acylation for albumin binding. Semaglutide is the textbook case. The molecule carries two changes from native GLP-1 (alanine to 2-aminoisobutyric acid at position 8 to resist DPP-4, lysine to arginine at position 34) and a C18 fatty diacid attached at lysine 26 through a hydrophilic spacer (Lau et al., J Med Chem 2015, PMID 26308095). The lysine 26 acylation drives high-affinity binding to human serum albumin, which extends the plasma half-life from approximately 13 hours for liraglutide to roughly 168 hours for semaglutide (Knudsen and Lau, Front Endocrinol 2019, PMID 31031702). That is enough for once-weekly subcutaneous dosing but not enough for monthly.

Pushing the dose interval out to monthly requires more. Two strategies have produced human data:

1. Peptide-antibody conjugates. MariTide (maridebart cafraglutide) fuses a GLP-1 receptor agonist plus GIP receptor antagonist payload to an antibody fragment. The Fc fragment recycles through the neonatal Fc receptor, producing antibody-like half-life and supporting monthly dosing (Rosenstock et al., NEJM 2025, DOI 10.1056/NEJMoa2504214).
2. Ultra-long-acting peptide engineering. Berobenatide does not use an antibody conjugate. Pfizer describes it as an ultra-long-acting injectable GLP-1 RA peptide. The structural specifics have not been disclosed in detail, but the architecture is consistent with a peptide carrier strategy rather than a Fc fusion. That is the meaningful chemistry distinction from MariTide.

The practical consequence: berobenatide is a peptide that holds plasma concentration for weeks, MariTide is a peptide-antibody hybrid that holds for weeks for a different structural reason, and the two compounds will likely have different distribution, immunogenicity, and manufacturing profiles. The weight-loss numbers do not have to predict tolerability or safety the same way.

Berobenatide vs MariTide vs weekly GLP-1s

The most useful frame for the VESPER-3 result is against the other Phase 2 and Phase 3 weight-management readouts in the GLP-1 class. Numbers below normalize to maximum dose and longest available follow-up.

Three readings come out of that table.

Berobenatide trails the weekly maximum class numbers. A 12.3 percent placebo-adjusted result at 28 weeks sits below the weekly tirzepatide and weekly retatrutide top-dose data. The 15.9 percent extension number on weekly berobenatide lands closer to the weekly semaglutide envelope. Phase 3 has to answer whether the dosing convenience justifies the trade.

The MariTide weight loss number is higher. MariTide's up-to-20 percent at 52 weeks is the leading monthly figure to date. The trade-off is that Amgen revised the Phase 3 dosing plan after a Phase 2 tolerability profile that ran high on vomiting and treatment discontinuation. Berobenatide's reported tolerability looks cleaner.

The compounds are not interchangeable. MariTide is a dual mechanism (GLP-1 agonism plus GIP antagonism). Berobenatide is a GLP-1 mono-agonist. The mechanistic difference will surface in subgroup analyses for T2D HbA1c, body composition, and GI tolerability once Phase 3 reads out.

Tolerability: cleaner than the class

The distinguishing claim from the VESPER-3 summary is the gastrointestinal tolerability profile. Pfizer reports:

• 83% of treated participants had no or only mild key gastrointestinal adverse events
• A transient mild increase in nausea and vomiting occurred upon transition to monthly dosing, then resolved with continued dosing
• Discontinuation rates were low even under a rapid titration protocol without the option to step down
• Overall safety was consistent with the GLP-1 class

That is a meaningfully softer GI profile than the Phase 2 results reported for retatrutide at 12 mg (about 35 percent nausea at maximum dose) and the upper end of Phase 2 MariTide, where high-dose vomiting and discontinuation drove the Phase 3 dosing redesign. It is closer to the STEP-1 semaglutide profile.

Two caveats. First, the 83 percent figure is the trial-level summary statistic. A peer-reviewed paper will give the breakdown by dose and by transition. Second, the weekly-to-monthly transition is a real signal worth watching. A monthly peak-trough cycle looks different from a weekly steady-state, and any tolerability question that surfaces in Phase 3 is likely to cluster at the transition or in the trough.

Note: Phase 2b press releases tend to overstate efficacy and understate safety on average. The published manuscript is where the dose-by-dose breakdown will land. Read the trial numbers above as directional, not final.

What is still missing from the public data

The press release is short and the peer-reviewed paper is not out. The questions that will get answered in the Phase 3 dataset, and that researchers should not extrapolate from the 28-week summary, include:

• Dose-response curve. The release confirms all four monthly arms beat placebo but does not publish the lower-dose efficacy numbers. The shape of the curve at 2.4 and 3.6 mg matters for the Phase 3 dose-finding logic.
• Body composition. Weight loss is a denominator. The lean-mass to fat-mass split, hip and waist measurements, and DEXA subgroup are all standard in modern obesity trials. None are public.
• Cardiometabolic markers. HbA1c, lipid panels, blood pressure, waist circumference, and CRP changes have not been reported in the public summary.
• Anti-drug antibodies. Any long-acting peptide carries immunogenicity risk. The Phase 2b dataset should include ADA monitoring, but it is not in the release.
• Compound architecture. Pfizer has not disclosed the specific structural modifications that extend berobenatide's half-life into monthly territory. That detail will land with the manuscript.
• Head-to-head data. There is no head-to-head trial against semaglutide, tirzepatide, MariTide, or retatrutide. The Phase 3 program is unlikely to fund one in the near term.

What comes next

Pfizer has committed to a Phase 3 program of up to ten studies for berobenatide covering chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea. The pivotal weight-management trial is currently recruiting.

If the Phase 3 efficacy curve lands anywhere near the VESPER-1 extension number on weekly dosing, the regulatory submission will likely follow the weight-management track that semaglutide and tirzepatide already cleared. If monthly-dose maintenance holds while weekly performance attenuates, the differentiating claim becomes adherence and convenience rather than efficacy magnitude.

Two competitive dynamics will define the monthly category over the next 18 to 24 months:

1. MariTide Phase 3. Amgen revised the dosing plan after Phase 2 tolerability data. The Phase 3 readout will define whether the monthly category is one compound or two.
2. Oral GLP-1s. Orforglipron Phase 3 evidence has reshaped the long-term competitive question. A daily pill that reaches semaglutide-class efficacy reduces the convenience advantage of monthly injection compared with weekly injection.

Practical takeaways

For researchers tracking the GLP-1 pipeline, berobenatide changes three things:

1. Monthly is feasible. The proof-of-concept is now two independent compounds (berobenatide and MariTide) with monthly maintenance dosing supporting clinically meaningful weight loss in human trials.
2. The efficacy-convenience trade-off is now quantified. Weekly tirzepatide and weekly retatrutide deliver larger numbers. Monthly berobenatide trades roughly four to eight percentage points of weight loss for dosing frequency. Patient-preference work in Phase 3 will tell us how that trade plays.
3. The peer-reviewed paper will matter. A Phase 2b press release is not a peer-reviewed dataset. Wait for the manuscript before adjusting any framing on long-term safety, dose response, or comparative tolerability.

For the current research market, none of the FDA-approved or compounded weekly GLP-1s (semaglutide, tirzepatide, retatrutide) are obsoleted by this readout. Berobenatide is at least 18 to 24 months from any potential regulatory submission, and Pfizer has not committed to a US filing timeline as of the June 2026 release.

For researchers running comparative protocols

If you are designing a comparative obesity protocol and want to model class-leading numbers, the weekly compounds remain the operational reference. Semaglutide and tirzepatide are both available from our research partner at COA-verified purity with 50% off using code ENHANCED, and dosing math for either compound is straightforward with the reconstitution calculator.

• Semaglutide research guide
• Tirzepatide research guide
• Retatrutide research guide
• MariTide Phase 2 evidence breakdown
• Tirzepatide vs Semaglutide SURMOUNT-5
• Orforglipron Phase 3 evidence
• Retatrutide TRIUMPH-1 and TRIUMPH-4 topline

Disclaimer

This article is provided for research and educational purposes only. Berobenatide is not approved for human use in any jurisdiction and is currently in Phase 2b clinical development. Nothing in this article is medical advice or a recommendation to use any compound described. Trial data summarized here is drawn from press releases and conference presentations that have not yet been peer-reviewed; numbers and safety conclusions may change with publication. Consult a qualified healthcare professional before any decision involving any of these compounds.